Hahn et al reported a prognostic score for patients with Hodgkin's disease undergoing autologous hematopoietic cell transplantation (AHCT). This can help to identify a patient who may benefit from more aggressive management. The authors are from Roswell Park Cancer Institute, Medical College of Wisconsin, University Hospitals Case Medical Center, Stanford University and Queen Mary University of London.
NOTE: The parameters for the model are shared with the model of Hahn et al for bone marrow transplant and the model of Satwani et al for stem cell transplant.
Patient selection: Hodgkin's disease following autologous hematopoietic cell transplant
Outcome: 4-year progression-free survival (PFS)
Parameters:
(1) number of prior chemotherapy regimens
(2) extranodal involvement before transplant
(3) Karnofsky performance status prior to transplant (from 10 to 100)
(4) chemotherapy response
Parameter
Finding
Points
number of prior chemotherapy regimens
1 or 2
0
>= 3 (3 to 5)
2
extranodal involvement
no
0
yes
2
Karnofsky performance
>= 90
0
< 90
1
chemotherapy response
sensitive
0
resistant
1
total score =
= SUM(points for all 4 parameters)
Interpretation:
• minimum score: 0
• maximum score: 6
Total Score
Risk Group
4-Year PFS
0
low
71%
1 to 3
intermediate
60%
4 to 6
high
42%
To read more or access our algorithms and calculators, please log in or register.
